Engineering selective PI3Kγ inhibitors with antitumor and immunomodulatory potentials.

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Phosphoinositide 3-kinase gamma (PI3Kγ) is crucial in macrophage functions and linked to cancer progression.
• Targeting PI3Kγ offers a potential strategy for cancer therapy.

Purpose of the Study:

• To design and synthesize novel, selective PI3Kγ inhibitors.
• To evaluate the anti-melanoma efficacy and immunomodulatory effects of these inhibitors.

Main Methods:

• Machine learning and molecular hybridization were employed to generate PI3Kγ inhibitors.
• In vitro and in vivo assays were used to assess anti-melanoma activity and toxicity.
• Mechanism of action was investigated by analyzing signaling pathways and macrophage polarization.

Main Results:

• A novel indole-based inhibitor, IHA-5f, showed picomolar potency and high selectivity for PI3Kγ.
• IHA-5f exhibited significant anti-melanoma effects in vitro and in vivo with minimal toxicity.
• IHA-5f suppressed tumor cell proliferation and migration, induced apoptosis via the PI3Kγ/AKT/NF-κB pathway, and inhibited M2 macrophage polarization.

Conclusions:

• Novel PI3Kγ inhibitors, exemplified by IHA-5f, possess potent anti-melanoma activity.
• IHA-5f acts as both a direct antitumor agent and an immunomodulator by targeting PI3Kγ.
• PI3Kγ inhibitors represent a promising therapeutic avenue for melanoma treatment.